Why the study?
Does GLP1RA therapy reduce all-cause mortality and cardiovascular outcomes in high cardiovascular risk patients with type 2 diabetes?
Does GLP1RA therapy reduce all-cause mortality and cardiovascular outcomes in high cardiovascular risk patients with type 2 diabetes?
GLP1RA therapy reduces all-cause mortality in high cardiovascular risk patients with type 2 diabetes, despite no significant impact on individual cardiovascular endpoints in this analysis.
GLP1RA therapy when compared to placebo reduced all-cause mortality in high cardiovascular risk patients with type 2 diabetes. They did not impact cardiovascular mortality, nonfatal MI, nonfatal stroke, or heart failure hospitalizations.
No takes yet. Share an insight, caveat, or question.
Peterson et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: